Biohaven presents data for BHV-1510 at ESMO

Biohaven (BHVN) announced that it presented clinical safety and efficacy data for BHV-1510 at the 2025 European Society for Medical Oncology, ESMO, Immuno-Oncology Congress, taking place from December 10-12, 2025, in London, United Kingdom. The presentation highlights Biohaven’s novel next-generation trophoblast cell surface antigen 2 directed antibody drug conjugate, ADC, BHV-1510, in combination with Regeneron’s anti-PD-1 cemiplimab demonstrating efficacy and manageable safety across several tumors. Across all doses BHV-1510, was generally well tolerated with a safety profile differentiated from other Trop-2 ADCs. The rate of neutrophil count decrease was low and manageable; all Grade, 12.9%. Similarly, the rates of treatment emergent diarrhea and alopecia were low; all Grade, 6.5% and 9.7% respectively. The most frequent toxicity observed was oral mucositis/stomatitis all Grade, 59.1% in the Q3W regimen and all Grade, 33.3% in the D1D8Q3W regimen. This is a well-known class effect which is manageable. Importantly, there were no cases of interstitial lung disease, and no participants discontinued treatment due to an adverse event.